Landscape Capital Management L.L.C. Takes $227,000 Position in Solventum Co. (NYSE:SOLV)

Landscape Capital Management L.L.C. acquired a new stake in shares of Solventum Co. (NYSE:SOLV) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 3,258 shares of the company’s stock, valued at approximately $227,000.

Several other institutional investors have also modified their holdings of the business. Deseret Mutual Benefit Administrators acquired a new stake in Solventum in the 2nd quarter valued at approximately $25,000. Hollencrest Capital Management acquired a new stake in Solventum in the 2nd quarter valued at approximately $25,000. Partnership Wealth Management LLC acquired a new stake in Solventum in the 2nd quarter valued at approximately $26,000. Richard W. Paul & Associates LLC acquired a new stake in Solventum in the 2nd quarter valued at approximately $26,000. Finally, Family Firm Inc. acquired a new stake in Solventum in the 2nd quarter valued at approximately $26,000.

Solventum Price Performance

Shares of NYSE SOLV opened at $71.58 on Tuesday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The stock has a 50 day moving average of $70.52 and a 200-day moving average of $62.35.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus assumed coverage on Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Wells Fargo & Company dropped their target price on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. The Goldman Sachs Group boosted their price target on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. Wolfe Research initiated coverage on Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. Finally, Morgan Stanley boosted their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $68.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.